Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Significant Increase in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 269,200 shares, an increase of 383.3% from the January 15th total of 55,700 shares. Based on an average daily volume of 691,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 14.6% of the company’s shares are short sold.

Vincerx Pharma Stock Up 2.4 %

NASDAQ VINC opened at $1.28 on Friday. The stock’s 50 day moving average is $3.19 and its 200 day moving average is $7.97. The firm has a market capitalization of $2.87 million, a PE ratio of -0.06 and a beta of 1.37. Vincerx Pharma has a twelve month low of $1.18 and a twelve month high of $187.44.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.